News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

1Amazon is Considering a $9 Billion Deal to Acquire Satellite Communications Company Globalstar. Here's Why Amazon, Apple, and Tesla Investors Should Pay Attention.2Exxon’s Guyana-Permian Engine Fuels 21% Earnings Growth—Is the 24 P/E Already Discounting a Squeeze?3Bitcoin’s Movement Compared to Oil’s Rally: Evaluating a Risk-Off Scenario
3 Top Performing Stocks Set for Significant Growth at This Moment
101 finance·2026/03/11 20:03

Bitcoin to $78K? Pro traders price in less than 17% odds of a breakout
Cointelegraph·2026/03/11 20:03
Q32 Bio Breaks Out — But Can It Hold the Momentum?
101 finance·2026/03/11 19:54
Harvey’s Venture Fund Debut: Strategic Sector Shift or Bold Bet on Emerging Ecosystems?
101 finance·2026/03/11 19:40
Is the Options Market Suggesting a Surge in Air Lease Shares?
101 finance·2026/03/11 19:36
BNTX Stock Tumbles as Founders Exit, Testing $91 Support
101 finance·2026/03/11 19:36
Allos Moves Toward Dividend-Driven Stability Amid Ongoing Uncertainty in Brazil's Economy
101 finance·2026/03/11 19:36
Flash
21:46
Regenerative medicine giant Organogenesis Holdings Inc (ORGO) recently announced the successful completion of a key meeting with the U.S. Food and Drug Administration (FDA).The two parties reached a consensus on the clinical development pathway of Renu® regenerative cell technology for the treatment of knee osteoarthritis pain. The company clearly stated that it will accelerate the regulatory submission process based on the meeting's guidance and plans to officially submit a Biologics License Application (BLA). This innovative therapy aims to target and repair knee cartilage tissue through a cell regeneration mechanism, providing a new non-surgical intervention option for hundreds of millions of osteoarthritis patients worldwide. This milestone event marks a significant breakthrough in the commercialization process of the Renu® product. Industry analysts pointed out that if approved for market launch, this product could reshape the market landscape of the orthopedic pain treatment sector. Influenced by this positive news, the company’s stock price showed an upward trend in after-hours trading.
21:42
(PAC) Fairshake: Holds $193 million in campaign funds ahead of the November 2026 midterm electionsJinse Finance reported that on April 7, the cryptocurrency-backed political action committee (PAC) Fairshake stated it had spent over $130 million on media buying for the 2024 election. The committee said in January that it has $193 million in campaign funds available through the November 2026 midterm elections. The organization is not the only group supporting cryptocurrency nationwide. Fellowship PAC claims to have raised "over $100 million" from undisclosed backers closely linked with the cryptocurrency industry, and on Wednesday, announced the appointment of Tether executive Jesse Spiro as chairperson.
21:24
Bitcoin's 30-day average transaction fee drops to the lowest level since 2011The 30-day average transaction fee for Bitcoin has dropped to 2.5 BTC per day, the lowest level since 2011, indicating weak on-chain demand. (Cointelegraph)
News